Overview
Study to Evaluate the Efficacy and Safety of 0.1% and 0.03% Tacrolimus Ointment Administered in Adults With Moderate to Severe Atopic Dermatitis
Status:
Completed
Completed
Trial end date:
2005-02-01
2005-02-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The objective of this study is to assess the efficacy and safety of 0.1% and 0.03% Tacrolimus ointment for 12 months in adults with moderate to severe atopic dermatitis.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Astellas Pharma IncTreatments:
Tacrolimus
Criteria
Inclusion Criteria:- Patient may be male or female of any ethnic group
- Patient without restricted legal competence, and suffers from moderate to severe
atopic dermatitis (Rajka/Langeland score of at least 4.5)
- Patient known to be responsive to topical steroids
- Patient is capable of understanding the purposes and risks of the trial and has given
written Informed Consent
- Female patients of childbearing potential must agree to maintain adequate birth
control practice during the trial period and during the first four weeks after the end
of the study
- Patient meets the following criteria:
- Topical corticosteroids
- Systemic corticosteroids (for the treatment of AD only)
- Systemic non-steroidal immunosuppressants (e.g. cyclosporine, methotrexate)
- Other investigational drugs
- Light Treatments (UVA, UVB)
- Patient has not taken and agrees not to take for the complete study period any
medication or therapy prohibited by the protocol
Exclusion Criteria:
- Patient has a genetic epidermal barrier defect such as Netherton's syndrome or
generalised erythroderma
- Patient is pregnant or breast-feeding
- Patient has a skin infection on the affected (and to be treated) area
- Patient has a known hypersensitivity to macrolides in general, to tacrolimus or any
excipient of the ointment
- Patient is simultaneously participating in any other drug trial or less than 28 days
have passed between the end of the previous trial and this one
- Any form of substance abuse (including drug or alcohol abuse),psychiatric disorder or
condition which, in the opinion of the investigator, may invalidate the communication
with the investigator
- Patient is known to be HIV positive